NVCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now: the CMS billing-privilege revocation is an immediate, material revenue hit with uncertain reinstatement timing, which can keep the stock pressured near-term.", "Technical setup is deeply oversold (RSI_6 ~8) but trend is still decisively bearish (bearish MAs + worsening MACD), so \u201ccheap\u201d can keep getting cheaper for an impatient buyer.", "Options market is pricing high risk (IV extremely elevated) and today\u2019s flow skews defensive (put volume dominates), signaling traders are still hedging/downside-positioning.", "Intellectia Proprietary Trading Signals: no confirming buy timing today (AI Stock Picker: no signal; SwingMax: no recent signal), so there\u2019s no strong tactical edge to buy the dip immediately."]
["Trend: Bearish (SMA_200 > SMA_20 > SMA_5) confirming a sustained downtrend.", "Momentum: MACD histogram -0.342 and negatively expanding \u2192 downside momentum is strengthening, not stabilizing yet.", "Overbought/oversold: RSI_6 at 8.263 \u2192 extremely oversold; this can trigger bounces, but it\u2019s not a trend-reversal confirmation by itself.", "Key levels: Immediate support S2 ~9.421 (near current 9.96); resistance overhead at S1 ~10.431 then pivot ~12.065. A reclaim of ~12 is needed to improve structure."]
on 2026-02-26 pre-market could be a catalyst if management provides a clear timeline/impact mitigation plan."]
["Primary overhang: CMS revoked billing privileges; expected monthly revenue decline of ~ $13M starting 2025-12-17 until reinstatement\u2014timing uncertain.", "Event-driven credibility/compliance risk: revocation tied to an administrative issue during revalidation, raising concerns about process controls.", "Price action confirms risk-off: -13.75% regular-session drop with bearish trend signals suggests institutions may continue to de-risk until clarity returns."]
["Latest quarter (2025/Q3): Revenue $167.204M, +7.81% YoY\u2014growth is positive but not enough to offset the current CMS-related shock.", "Profitability: Net income -$37.27M (loss narrowed ~21.92% YoY) and EPS -0.33 (improved ~17.86% YoY) \u2192 improving trend, still loss-making.", "Margins: Gross margin 73.25%, down ~5.10% YoY \u2192 margin compression is a mild negative alongside the current reimbursement/billing disruption."]
["Recent analyst action: Evercore ISI (2026-01-05) lowered price target to $20 from $22 but maintained Outperform\u2014still sees upside vs current price, but trimmed expectations.", "Wall Street pro view (pros): maintained Outperform suggests belief in recovery/upside once operational issues clear; the target implies large potential upside from ~$10.", "Wall Street con view (cons): target cut and sector/policy concerns highlight sensitivity to reimbursement/administrative factors\u2014exactly the risk now materializing via CMS billing disruption.", "Influential trading check: no recent Congress trading data available; hedge funds noted as neutral, offering no near-term sponsorship signal."]
